To extend the drug effect analysis to additional ALK-inhibitors beyond crizotinib, we also tested ceritinib, entrectinib, ensartinib and lorlatinib on MM cells from six additional patients (Fig. 3I, J). Here, ALK is linked to Miyoshi myopathy.